FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955553513> ?p ?o ?g. }

• W2955553513 abstract "Direct acting antiviral (DAA) regimens of 12 weeks result in HCV clearance in vast majority of patients across genotypes. We previously demonstrated an ultra-short regimen of 4 weeks DAA cleared HCV in a subset of patients. Here, we hypothesized that individual level of antiviral immunity differentially influenced viral clearance and investigated biomarkers of a successful response. Cohorts of HCV patients treated for 4 weeks with DAA therapy who either achieved sustained virologic response (SVR) or relapsed were compared at baseline and at end of therapy (EOT) for immune cell phenotypes and HCV specific immunity. Higher levels of PD-1+ CD8+ and CD4+ T lymphocytes co-expressing inhibitory receptors (IR) were present at baseline and at EOT in HCV patients who eventually achieved SVR compared with those who relpased. HCV specific CD8+ T cells were predominantly contained within these IR expressing PD-1+ subsets. Patients in the SVR group had significantly higher CD8+ T cell degranulation in response to HCV peptides at baseline and higher levels of cytokine producing T cells at EOT time-point, relative to those who relapsed. In ex vivo cultures, PD-1+CD160+ CD8+ T cells had higher HCV specific degranulation and PD-1+2B4+ CD8+ T cells had higher cytokine expression (IFNγ+TNFα+ or IFNγ+CD107a+) compared with single or no IR expressing subsets, indicating higher virus specific functional capacity of these subsets. Receiver operating characteristics curve (ROC) for baseline circulating frequencies of PD-1+CD160+, PD-1+Tim-3+ CD8+ T cells and PD-1+CD160+, PD-1+Blimp-1+, PD-1-CTLA4+ CD4+ T cells respectively, had associated C-statistics of 0.8214 and 0.9451 for discriminatin of patients who successfully cleared HCV with 4 weeks treatment. Thus, PD-1+ virus-specific CD8+ T cell subsets with cytotoxic capacity are present in a subset of chronic HCV infected individuals that associate with ability to achieve SVR, indicating role of immunity in DAA mediated viral clearance with short duration therapy." @default.
• W2955553513 created "2019-07-12" @default.
• W2955553513 creator A5015530556 @default.
• W2955553513 creator A5032276136 @default.
• W2955553513 creator A5041278934 @default.
• W2955553513 creator A5043752885 @default.
• W2955553513 creator A5046839352 @default.
• W2955553513 creator A5068553755 @default.
• W2955553513 date "2019-06-27" @default.
• W2955553513 modified "2023-10-18" @default.
• W2955553513 title "Peripheral PD-1+ T Cells Co-expressing Inhibitory Receptors Predict SVR With Ultra Short Duration DAA Therapy in HCV Infection" @default.
• W2955553513 cites W1575215698 @default.
• W2955553513 cites W1910384556 @default.
• W2955553513 cites W1993617345 @default.
• W2955553513 cites W2013646796 @default.
• W2955553513 cites W2013740977 @default.
• W2955553513 cites W2025741354 @default.
• W2955553513 cites W2028368003 @default.
• W2955553513 cites W2039772384 @default.
• W2955553513 cites W2043899250 @default.
• W2955553513 cites W2048088501 @default.
• W2955553513 cites W2058115636 @default.
• W2955553513 cites W2075973564 @default.
• W2955553513 cites W2082146590 @default.
• W2955553513 cites W2084446925 @default.
• W2955553513 cites W2098188322 @default.
• W2955553513 cites W2100990844 @default.
• W2955553513 cites W2106172678 @default.
• W2955553513 cites W2119978135 @default.
• W2955553513 cites W2120333669 @default.
• W2955553513 cites W2130259551 @default.
• W2955553513 cites W2143454433 @default.
• W2955553513 cites W2151063300 @default.
• W2955553513 cites W2152193720 @default.
• W2955553513 cites W2152441233 @default.
• W2955553513 cites W2163152566 @default.
• W2955553513 cites W2164783799 @default.
• W2955553513 cites W2216086010 @default.
• W2955553513 cites W2262571051 @default.
• W2955553513 cites W2584586929 @default.
• W2955553513 cites W2593802464 @default.
• W2955553513 cites W2610783335 @default.
• W2955553513 cites W2781766181 @default.
• W2955553513 cites W2788216918 @default.
• W2955553513 cites W2792607074 @default.
• W2955553513 cites W2891274730 @default.
• W2955553513 cites W2897075687 @default.
• W2955553513 doi "https://doi.org/10.3389/fimmu.2019.01470" @default.
• W2955553513 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6610534" @default.
• W2955553513 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31316516" @default.
• W2955553513 hasPublicationYear "2019" @default.
• W2955553513 type Work @default.
• W2955553513 sameAs 2955553513 @default.
• W2955553513 citedByCount "12" @default.
• W2955553513 countsByYear W29555535132019 @default.
• W2955553513 countsByYear W29555535132020 @default.
• W2955553513 countsByYear W29555535132021 @default.
• W2955553513 countsByYear W29555535132022 @default.
• W2955553513 countsByYear W29555535132023 @default.
• W2955553513 crossrefType "journal-article" @default.
• W2955553513 hasAuthorship W2955553513A5015530556 @default.
• W2955553513 hasAuthorship W2955553513A5032276136 @default.
• W2955553513 hasAuthorship W2955553513A5041278934 @default.
• W2955553513 hasAuthorship W2955553513A5043752885 @default.
• W2955553513 hasAuthorship W2955553513A5046839352 @default.
• W2955553513 hasAuthorship W2955553513A5068553755 @default.
• W2955553513 hasBestOaLocation W29555535131 @default.
• W2955553513 hasConcept C126322002 @default.
• W2955553513 hasConcept C142462285 @default.
• W2955553513 hasConcept C150903083 @default.
• W2955553513 hasConcept C154317977 @default.
• W2955553513 hasConcept C167672396 @default.
• W2955553513 hasConcept C170493617 @default.
• W2955553513 hasConcept C202751555 @default.
• W2955553513 hasConcept C203014093 @default.
• W2955553513 hasConcept C207001950 @default.
• W2955553513 hasConcept C2522874641 @default.
• W2955553513 hasConcept C26291073 @default.
• W2955553513 hasConcept C2776090121 @default.
• W2955553513 hasConcept C2778690821 @default.
• W2955553513 hasConcept C49802076 @default.
• W2955553513 hasConcept C55493867 @default.
• W2955553513 hasConcept C71924100 @default.
• W2955553513 hasConcept C86803240 @default.
• W2955553513 hasConcept C8891405 @default.
• W2955553513 hasConceptScore W2955553513C126322002 @default.
• W2955553513 hasConceptScore W2955553513C142462285 @default.
• W2955553513 hasConceptScore W2955553513C150903083 @default.
• W2955553513 hasConceptScore W2955553513C154317977 @default.
• W2955553513 hasConceptScore W2955553513C167672396 @default.
• W2955553513 hasConceptScore W2955553513C170493617 @default.
• W2955553513 hasConceptScore W2955553513C202751555 @default.
• W2955553513 hasConceptScore W2955553513C203014093 @default.
• W2955553513 hasConceptScore W2955553513C207001950 @default.
• W2955553513 hasConceptScore W2955553513C2522874641 @default.
• W2955553513 hasConceptScore W2955553513C26291073 @default.
• W2955553513 hasConceptScore W2955553513C2776090121 @default.
• W2955553513 hasConceptScore W2955553513C2778690821 @default.
• W2955553513 hasConceptScore W2955553513C49802076 @default.
• W2955553513 hasConceptScore W2955553513C55493867 @default.

• next